Raven and BTI collaborate in cancer stem cell discovery

Under the terms of the agreement, Raven will license its proprietary whole cell immunization technology for use with Bioprocessing Technology Institute (BTI)’s stem cells. Raven will screen the resulting antibodies against its collection of cancer lines, including its cancer stem cell lines. Raven will have the rights to the antibodies BTI generates using Raven’s immunization technology for use in cancer therapeutics and diagnostics and BTI will retain the rights to the antibodies it raises for all other stem cell therapeutic areas.

George Schreiner, CEO of Raven, said: “We anticipate that this collaboration should yield a substantial number of novel monoclonal antibodies targeting cancer stem cells suitable for development by Raven biotechnologies and its partners.”